Prognostic Factors for All Types of Cancer Combined - Full Text View

Prognostic Factors for All Types of Cancer Combined (ProFaCo)

This study is currently recruiting participants.

Verified by Atrium Medical Center, June 2008

Sponsors and Collaborators:	Atrium Medical Center Maastricht University Medical Center
Information provided by:	Atrium Medical Center
ClinicalTrials.gov Identifier:	NCT00704587

Purpose

The purpose of this study is to investigate every possible applicability of flowcytometrical analysis in the intracellular detection of tumor-related material in activated macrophages in the broadest range of cancer types.

Condition
Cancer Occurence Cancer Recurrence Neo-Adjuvant Treatment Response Measurement

MedlinePlus related topics: Cancer

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	Flow Cytometrical Analysis of the Human Immune System to Assess Tumor-Related Material Piling up in Activated Macrophages in All Relevant Cancer Types.

Further study details as provided by Atrium Medical Center:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

white cells

tissue

plasma

serum

Estimated Enrollment:	520
Study Start Date:	November 2006
Estimated Study Completion Date:	November 2010
Estimated Primary Completion Date:	October 2010 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

all patients diagnosed or suspected of cancerous conditions in the broadest sense of the word

Criteria

Inclusion Criteria:

(Suspicion of) presence of cancer in the broadest sense of the word
Must be able to understand and sign written informed consent

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00704587

Contacts

Contact: Dennis Japink, MD	+31652252642	dennisjapink@gmail.com
Contact: Meindert Sosef, PhD, MD		meindert.sosef@planet.nl

Locations

Netherlands, Limburg
Atrium Medical Centre Parkstad	Recruiting
Heerlen, Limburg, Netherlands, 6401 PC
Principal Investigator: Dennis Japink, MD
Maastricht University Medical Centre	Recruiting
Maastricht, Limburg, Netherlands, 6202 AZ
Principal Investigator: Dennis Japink, MD

Sponsors and Collaborators

Atrium Medical Center

Maastricht University Medical Center

Investigators

Principal Investigator:

Dennis Japink, MD

Atrium Medical Centre Parkstad, Heerlen

More Information

Responsible Party:	Atrium Medical Centre Heerlen ( Dennis Japink )
Study ID Numbers:	ProFaCo, METC 06-p-47, MEC 08-02-030, NL14215.096.06
Study First Received:	June 23, 2008
Last Updated:	July 15, 2008
ClinicalTrials.gov Identifier:	NCT00704587
Health Authority:	Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Study placed in the following topic categories:

Recurrence

Additional relevant MeSH terms:

Disease Attributes
Pathologic Processes

ClinicalTrials.gov processed this record on January 16, 2009